



## Monday, May 16

### SESSION 1

**POSTER TIME** 9:45A – 1:15P

**PRESENTATION TIME** 12:15 – 1:15P

#### **BREAST CANCER HER2+**

Demographic and initial diagnostic staging of patients with HER2+ breast cancer

#### **BREAST CANCER HER2-**

Systemic antineoplastic treatment utilization among patients with advanced HER2- breast cancer

#### **BLADDER**

Demographic and initial diagnostic staging of patients with bladder cancer

### SESSION 2

**POSTER TIME** 3:00 – 6:30P

**PRESENTATION TIME** 5:30 – 6:30P

#### **BREAST TNBC**

Systemic antineoplastic treatment utilization among patients with triple negative breast cancer

#### **PROSTATE**

Demographic and initial diagnostic staging of patients with prostate cancer

#### **NSCLC**

Biomarker testing rates among patients with advanced non-squamous non-small cell lung cancer treated within large community health systems in the US

Research presented from the Syapse Learning Health Network™  
across large community health systems in the US



## Tuesday, May 17

### SESSION 3

**POSTER TIME** 9:45A – 1:15P

**PRESENTATION TIME** 12:15 – 1:15P

#### BREAST CANCER HER2-

Demographic and initial diagnostic staging of patients with HER2- breast cancer

#### COLORECTAL

Systemic antineoplastic treatment utilization among patients with colorectal cancer

### SESSION 4

**POSTER TIME** 3:00 – 6:30P

**PRESENTATION TIME** 5:30 – 6:30P

#### BREAST CANCER HER2+

Systemic antineoplastic treatment utilization among patients with advanced HER2+ breast cancer

#### OVARIAN

Demographic and initial diagnostic staging of patients with ovarian cancer

## Wednesday, May 18

### SESSION 5

**POSTER TIME** 9:00A – 12:45P

**PRESENTATION TIME** 9:00 – 10:00A

#### BREAST CANCER TNBC

Demographic and initial diagnostic staging of patients with triple negative breast cancer

#### COLORECTAL

Demographic characteristics of patients diagnosed with colorectal cancer in early stages versus late stages

#### NSCLC

Rapid diversification of immune checkpoint inhibitor usage in community health systems in the US following new drug approvals